Diagnosis and management of acute myeloid leukemia with mutated CEBPA using CEBPA-Trass, a targeted sequencing approach

Acute myeloid leukemia (AML) with mutated CEBPA (CEBPA-AML) was first recognized as a distinct subtype associated with favorable prognosis in 2002, and its diagnostic criteria and clinical management have been refined over time. However, several challenges remain, including the lack of accurate mutation-based methods for measurable residual disease (MRD) detection. Here, we developed a targeted next-generation sequencing approach for the CEBPA gene, which uses adapter-free PCR amplification of hotspot regions followed by paired-end sequencing to improve analytical performance (termed CEBPA-Trass), and evaluated its clinical performance in samples from the WT1-AM-04 study. CEBPA-Trass successfully detected a cryptic long insertion missed by conventional short-read sequencing. Analytical validation showed higher background for missense variants, whereas insertions or deletions involving three or more base pairs were rarely detected in negative controls and typically below 10⁻⁴, indicating high analytical specificity. Dilution experiments further showed linear detection of insertions or deletions involving three or more base pairs with a limit of detection of 10⁻⁴ -10⁻⁵, comparable to the sensitivity of real-time PCR-based MRD assays, and aligned with the in-frame mutation patterns currently associated with favorable-risk CEBPA-AML. Clinically, CEBPA-Trass-based MRD assessment significantly stratified relapse risk after both first and last consolidation therapy. Specifically, the assessment after last consolidation showed that more than 80% of MRD-positive patients relapsed, whereas more than 80% of MRD-negative patients remained in remission for over two years. These findings suggest that CEBPA-Trass enables accurate mutation-based MRD monitoring and may improve both the diagnosis and risk stratification of patients with CEBPA-AML.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-18
DOI
https://doi.org/10.1182/bloodadvances.2026021717
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Diagnosis and management of acute myeloid leukemia with mutated CEBPA using CEBPA-Trass, a targeted sequencing approach

Hitoshi Hanamoto, Osamu Imataki, Tatsuya Imi, Daisuke Motooka et al.
Blood Advances
Acute Myeloid Leukemia Research
article

Diagnosis and management of acute myeloid leukemia with mutated CEBPA using CEBPA-Trass, a targeted sequencing approach

Hitoshi Hanamoto, Osamu Imataki, Tatsuya Imi, Daisuke Motooka, Norimitsu Kadowaki, Akihiro Tsuboi, Yuta Katayama, Hideaki� Yoshimura, Kensuke Usuki, Haruo Sugiyama, Shigeki Ito, Noboru Asada, Atsushi Kumanogoh, Fumihiro Fujiki, Junya Kuroda, Yasuhiko Shibasaki, Yusuke Oji, Hiroki Hosoi, Jun Nakata, Shuichi Ota, Takayuki Ikezoe, Ryota Imanaka, Masahiko Fukatsu, Atsushi� Satake, Masayoshi Masuko, Taku Tsukamoto, Makoto Onizuka, Tatsuo Oyake, Soyoko Morimoto, Yoshiki Nakae, Kazunori Murai, Yuki Takada, Hiroko Nakajima, Takeshi Maeda, Takashi Sonoki, Yukio Oka, Manabu Kawakami, Hiroyuki Yamano
article en

Abstract

Acute myeloid leukemia (AML) with mutated CEBPA (CEBPA-AML) was first recognized as a distinct subtype associated with favorable prognosis in 2002, and its diagnostic criteria and clinical management have been refined over time. However, several challenges remain, including the lack of accurate mutation-based methods for measurable residual disease (MRD) detection. Here, we developed a targeted next-generation sequencing approach for the CEBPA gene, which uses adapter-free PCR amplification of hotspot regions followed by paired-end sequencing to improve analytical performance (termed CEBPA-Trass), and evaluated its clinical performance in samples from the WT1-AM-04 study. CEBPA-Trass successfully detected a cryptic long insertion missed by conventional short-read sequencing. Analytical validation showed higher background for missense variants, whereas insertions or deletions involving three or more base pairs were rarely detected in negative controls and typically below 10⁻⁴, indicating high analytical specificity. Dilution experiments further showed linear detection of insertions or deletions involving three or more base pairs with a limit of detection of 10⁻⁴ -10⁻⁵, comparable to the sensitivity of real-time PCR-based MRD assays, and aligned with the in-frame mutation patterns currently associated with favorable-risk CEBPA-AML. Clinically, CEBPA-Trass-based MRD assessment significantly stratified relapse risk after both first and last consolidation therapy. Specifically, the assessment after last consolidation showed that more than 80% of MRD-positive patients relapsed, whereas more than 80% of MRD-negative patients remained in remission for over two years. These findings suggest that CEBPA-Trass enables accurate mutation-based MRD monitoring and may improve both the diagnosis and risk stratification of patients with CEBPA-AML.

Blood Advances
Kanazawa University (JP), Osaka Gakuin University (JP), Kansai Medical University (JP), Fukushima Medical University (JP), Tokai University (JP), Okayama University (JP), Iwate Medical University (JP), Wakayama Medical University (JP), Kagawa University (JP), Osaka City University (JP), Kyoto Prefectural University of Medicine (JP), Kurashiki Central Hospital (JP), Iwate Prefectural Central Hospital (JP), Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP), Sapporo Hokuyu Hospital (JP), Nippon Life Hospital (JP), Teikyo University Hospital, Mizonokuchi (JP), Kindai University Nara Hospital (JP), Research Institute for Microbial Diseases, The University of Osaka (JP), Niigata University (JP), Teikyo University (JP), Kindai University (JP), The University of Osaka (JP)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon